Procter & Gamble Health Ltd

Procter & Gamble Health Ltd

₹ 5,600 -0.08%
11 Dec 3:54 p.m.
About

P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.[1]

Key Points

Strong Brand Portfolio
Company is one the India’s largest VMS companies, manufacturing and marketing vitamins, minerals and supplements. It has a strong portfolio of various pharma brands such as Evion, Neurobion, Seven seas, Nasivion, Polybion, Cosome and Livogen. [1]

  • Market Cap 9,296 Cr.
  • Current Price 5,600
  • High / Low 5,836 / 4,637
  • Stock P/E 41.0
  • Book Value 324
  • Dividend Yield 1.07 %
  • ROCE 45.0 %
  • ROE 33.5 %
  • Face Value 10.0

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 32.1%
  • Company has been maintaining a healthy dividend payout of 110%

Cons

  • Stock is trading at 17.3 times its book value
  • The company has delivered a poor sales growth of 6.28% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
273 278 268 296 298 310 321 301 305 310 252 284 313
195 216 199 237 207 201 241 256 216 208 185 236 199
Operating Profit 78 62 69 59 91 109 80 45 89 102 67 48 114
OPM % 29% 22% 26% 20% 31% 35% 25% 15% 29% 33% 27% 17% 36%
3 5 2 3 3 5 5 5 6 5 2 -18 3
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 7 7 6 7 7 8 6 6 6 7 7 7 6
Profit before tax 74 60 65 55 87 105 79 44 88 100 63 23 111
Tax % 25% 25% 21% 25% 26% 27% 25% 32% 26% 28% 26% 26% 26%
55 45 51 41 64 77 59 30 66 72 47 17 82
EPS in Rs 33.36 27.01 30.82 24.81 38.35 46.27 35.66 17.96 39.50 43.42 28.05 10.11 49.60
Raw PDF

Profit & Loss

Figures in Rs. Crores

Dec 2013 Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Jun 2020 18m Jun 2021 Jun 2022 Jun 2023 Jun 2024 TTM
798 867 940 993 698 849 927 1,356 1,009 1,114 1,230 1,151 1,160
721 809 855 877 621 701 723 1,037 762 846 905 845 828
Operating Profit 77 59 85 116 77 148 204 319 246 268 325 307 331
OPM % 10% 7% 9% 12% 11% 17% 22% 24% 24% 24% 26% 27% 29%
21 20 22 24 74 768 48 66 18 13 18 -5 -7
Interest 0 0 0 0 0 0 0 0 1 0 1 1 1
Depreciation 10 13 23 25 19 21 17 29 30 27 28 27 27
Profit before tax 88 67 83 115 132 895 234 355 233 253 314 273 297
Tax % 37% 35% 36% 31% 29% 6% 32% 28% 24% 24% 27% 26%
56 43 54 79 94 839 159 254 177 193 229 201 218
EPS in Rs 33.66 26.04 32.27 47.67 56.57 505.27 95.64 153.07 106.51 115.98 138.24 121.08 131.18
Dividend Payout % 25% 23% 23% 23% 27% 87% 0% 150% 122% 45% 69% 215%
Compounded Sales Growth
10 Years: 4%
5 Years: 6%
3 Years: 5%
TTM: -6%
Compounded Profit Growth
10 Years: 14%
5 Years: -24%
3 Years: 7%
TTM: -2%
Stock Price CAGR
10 Years: 21%
5 Years: 6%
3 Years: 2%
1 Year: 12%
Return on Equity
10 Years: 28%
5 Years: 27%
3 Years: 32%
Last Year: 33%

Balance Sheet

Figures in Rs. Crores

Dec 2013 Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024
Equity Capital 17 17 17 17 17 17 17 17 17 17 17 17
Reserves 506 538 575 647 717 1,524 800 890 687 600 734 522
0 0 0 0 0 0 0 0 8 3 12 10
125 154 192 215 258 219 250 269 275 269 338 247
Total Liabilities 648 708 784 879 991 1,759 1,067 1,176 986 888 1,101 794
85 110 132 111 115 104 101 101 104 112 144 128
CWIP 9 28 7 30 9 17 11 21 39 41 32 6
Investments 24 24 42 28 70 0 0 0 0 0 0 0
530 547 603 711 797 1,639 954 1,053 843 736 925 660
Total Assets 648 708 784 879 991 1,759 1,067 1,176 986 888 1,101 794

Cash Flows

Figures in Rs. Crores

Dec 2013 Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024
0 5 83 107 54 -130 235 247 170 236 228
7 11 -68 -75 -48 1,270 165 -32 -26 -22 -7
-5 -17 -12 -15 -22 -30 -883 -387 -289 -98 -418
Net Cash Flow 3 -1 4 17 -16 1,109 -483 -172 -145 116 -197

Ratios

Figures in Rs. Crores

Dec 2013 Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024
Debtor Days 38 44 49 39 64 28 30 26 22 27 34 27
Inventory Days 153 162 140 145 243 154 139 113 138 124 136 120
Days Payable 37 40 55 67 128 124 106 105 209 185 239 184
Cash Conversion Cycle 154 166 134 118 179 58 63 34 -49 -34 -69 -37
Working Capital Days 70 74 69 52 94 42 22 23 9 18 16 20
ROCE % 18% 12% 15% 18% 16% 78% 20% 29% 29% 38% 45% 45%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82%
5.97% 6.57% 6.47% 6.05% 6.33% 6.72% 7.15% 7.38% 7.60% 6.24% 6.39% 6.61%
8.53% 7.91% 8.07% 12.62% 12.44% 12.31% 12.29% 12.30% 12.66% 13.72% 14.56% 14.84%
33.69% 33.71% 33.64% 29.51% 29.41% 29.14% 28.74% 28.50% 27.92% 28.22% 27.24% 26.74%
No. of Shareholders 65,53766,28965,72965,14863,83161,03058,85657,91956,73056,77855,92354,792

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents